Please ensure Javascript is enabled for purposes of website accessibility

Why Humanigen Stock Is Sinking Today

By Keith Speights – Sep 10, 2021 at 11:51AM

Key Points

  • Humanigen received a letter from the FDA rejecting EUA for lenzilumab.
  • The company is conducting another clinical study that it hopes will provide enough data to win EUA for its experimental COVID-19 drug.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.

What happened

Shares of Humanigen (HGEN -2.41%) were sinking 15.6% lower as of 11:36 a.m. EDT on Friday. The decline came after the clinical-stage biopharmaceutical company announced on Thursday that the U.S. Food and Drug Administration turned down Emergency Use Authorization for lenzilumab in treating newly hospitalized COVID-19 patients.

So what

Humanigen filed for U.S. EUA of lenzilumab on May 28. This submission was based on positive results from a phase 3 study of the experimental drug. Lenzilumab achieved a 54% improvement in the likelihood of survival without ventilation compared to placebo. 

A person wearing a white lab coat giving a thumbs down.

Image source: Getty Images.

However, the FDA didn't think that Humanigen's data was good enough for EUA. The agency stated in a letter to the company that it wasn't able to determine that the benefits of lenzilumab outweighed its risks.

This is a major setback for Humanigen. However, it isn't the end of the road for lenzilumab. CEO Cameron Durrant said Humanigen thinks another ongoing clinical study of the drug could provide the additional data needed to convince the FDA to grant EUA in treating hospitalized COVID-19 patients.

Now what

While Humanigen awaits results from its other study of lenzilumab, there could be other potential catalysts for the biotech stock in the meantime. The company expects to complete its U.K. regulatory submission for lenzilumab in treating COVID-19 by the end of this month. Humanigen is also moving forward with filing for authorization of the drug in the European Union.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Humanigen Inc Stock Quote
Humanigen Inc
HGEN
$0.14 (-2.41%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.